Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

St. Louis, Missouri Clinical Trials

A listing of St. Louis, Missouri clinical trials actively recruiting patient volunteers.

RESULTS

Found (29) clinical trials

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

This study will assess the effects of each of the two therapies given separately, both targeting amyloid, on cognition, global clinical status, and underlying pathology in participants at risk for the onset of clinical symptoms of Alzheimer's disease (AD). Cognitively unimpaired individuals with two APOE4 genes and age 60 to ...

Phase

1.42 miles

Learn More »

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Primary To evaluate the long-term safety and tolerability of seladelpar Secondary To evaluate the long-term efficacy of seladelpar

Phase

1.42 miles

Learn More »

Safety Pharmacokinetics and Efficacy of Dupilumab in Patients 6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

Part A (open-label, single-ascending-dose, sequential cohort phase 2 study): Primary objective is to characterize the safety and PK of dupilumab administered as a single dose in pediatric participants, 6 months to less than 6 years of age, with severe AD. Secondary objective is to evaluate the efficacy and immunogenicity of ...

Phase

1.78 miles

Learn More »

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately ...

Phase

2.9 miles

Learn More »

Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men

The purpose of this study is to evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW). This study will enroll HIV-uninfected MSM and TGW at risk for acquiring ...

Phase

2.9 miles

Learn More »

Tranexamic Acid Dosing in Adult Spinal Deformity Surgery

After consent is obtained and the patient is enrolled in the trial, patients will be assigned de-identified, unique identification (ID) numbers. Randomization of these IDs to either low or high dose TXA will occur via a computer generated random assignment. Given the variations that may exist in surgical technique (e.g. ...

Phase

2.9 miles

Learn More »

Clinical Trial to Evaluate the Efficacy Safety and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy

This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of RO7239361 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).

Phase

3.13 miles

Learn More »

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in combination with another study drug called ublituximab with or without bendamustine and TGR-1202 alone as a possible treatment for Non-Hodgkin's Lymphoma (NHL) that has come back or that has not responded to standard treatment.

Phase

3.13 miles

Learn More »

Selinexor in Advanced Liposarcoma

In the Phase 2 portion of the study, 57 patients were randomized to selinexor (60 mg) or placebo at a 1:1 allocation ratio. In the Phase 3 portion of the study, approximately 222 patients will be randomized to selinexor (60 mg) or placebo with a 2:1 allocation ratio. Patients who ...

Phase

3.13 miles

Learn More »